FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Cymbalta | Eli Lilly

FDA cancels meeting on new Cymbalta use

Tools

The FDA has canceled a meeting to review Eli Lilly's antidepressant Cymbalta for a new use against chronic pain, sending the company's stock downward. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about FDA   Cymbalta   Eli Lilly  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.